Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Osmol Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Osmol Therapeutics

Osmol Therapeutics

Osmol Therapeutics: Pioneering treatments for chemotherapy-induced peripheral neuropathy since 2016.

HQ
New Haven, CT, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Founded in 2016 and headquartered in New Haven, Connecticut, Osmol Therapeutics is dedicated to developing treatments to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). The company's core mission is to enhance care and transform lives by creating compassionate and effective treatment paths for patients at risk of these debilitating conditions. Osmol Therapeutics focuses on addressing critical challenges in cancer treatment, aiming to improve the quality of life for cancer patients worldwide.

Osmol Therapeutics has garnered attention for its innovative approach and has attracted notable investors and affiliations within the biotech and medical communities. The company's key achievements include advancing its lead therapeutic candidates through preclinical and early clinical development stages. By targeting the unmet needs in cancer supportive care, Osmol Therapeutics has made a significant impact on the field, offering hope to patients suffering from the side effects of life-saving chemotherapy treatments.

Osmol Therapeutics - Similar Companies

OS Therapies logo

OS Therapies

ostherapies.com

Camino Pharma logo

Camino Pharma

caminopharma.com

Omeros logo

Omeros

omeros.com

Palm Therapeutics logo

Palm Therapeutics

Ostentus Therapeutics logo

Ostentus Therapeutics

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Ovid Therapeutics logo

Ovid Therapeutics

ovidrx.com

Cairn Therapeutics logo

Cairn Therapeutics

OncoSpherix logo

OncoSpherix

oncospherix.com

Oscillo Biosciences logo

Oscillo Biosciences

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

Chase Therapeutics logo

Chase Therapeutics

Lysosomal Therapeutics logo

Lysosomal Therapeutics

lysosomaltx.com

PanTher Therapeutics logo

PanTher Therapeutics

panthertx.com

Orphan Star Therapeutics logo

Orphan Star Therapeutics

Osmol Therapeutics - Quick Facts

Who are Osmol Therapeutics' competitors?

Companies similar to Osmol Therapeutics include OS Therapies, Camino Pharma, Omeros and Palm Therapeutics.

When was Osmol Therapeutics founded?

Osmol Therapeutics was founded in 2016.

Where is Osmol Therapeutics' headquarters located?

Osmol Therapeutics' headquarters is located in New Haven, CT, US.

When was Osmol Therapeutics' last funding round?

Osmol Therapeutics' most recent funding round was for $5.2M (USD) in April 2022.

How much has Osmol Therapeutics raised to-date?

As of Apr 12, 2022, Osmol Therapeutics has raised a total of $5.2M (USD).

How many employees does Osmol Therapeutics have?

Osmol Therapeutics has 6 employees as of Feb 5, 2024.

Osmol Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Treatment
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified